Maximum Retail Price Approval: Bangladesh’s Price Control Step

1. Key takeaways

Bangladesh applies maximum retail price (MRP) approval to medical devices: the importer must apply to DGDA for MRP certification, which takes 30 to 40 days, and the approved MRP must then be marked on the product label in Bangladeshi taka. The selling price may not exceed the approved figure. This is an independent administrative approval that sits alongside registration; it is not obtained automatically with the registration certificate.

The requirement is easy to underestimate because it falls between two other processes. Registration is finished, the goods have cleared customs, and the product still cannot be sold at a lawful price until a separate approval has issued. Planning that treats MRP as a detail of labelling rather than as a stand-alone permit tends to discover the gap when the goods are already in the warehouse.

• Authority: DGDA, on application by the importer.
• Processing time: 30 to 40 days.
• Display: the approved MRP is marked on the label in taka.
• Ceiling: selling above the approved MRP is an offence, not a commercial decision.
• Separate instrument: the approval does not come with the registration certificate.

2. Legal basis

MRP certification is a step in the import process, documented in practice rather than in a standalone device regulation, and its documentary requirements reveal where it sits in the sequence: the application includes a copy of the registration certificate, the approved proforma invoice, a copy of the customs clearance, the commercial invoice and the bill of entry. The presence of customs documents means the application cannot be made until the goods have arrived and cleared. The labelling provisions of §7.2 Note 3 then govern when the MRP may be applied to the pack.

The penalty entry deserves a note on how to read it. The figures commonly reported derive from the 1982 ordinance, and the 2023 legislation restates the offence in new language; the operative text for any current matter is the gazette version, so the older figures should be treated as indicative of severity rather than as the current statement of the applicable penalty.

3. Expert insights

Insight 1: the MRP is a price ceiling, not a recommended retail price. What is approved is a maximum. A company may price freely below it, but not above it. That changes the filing strategy in a way that is not obvious: declare low and the room to raise prices later is limited; declare high and the figure may be reduced during approval. Neither error is recoverable quickly, because a revised MRP means a revised label. The sensible approach is to treat the declared figure as a 5-year decision rather than as a one-off pricing decision, and to support it with the pricing and exchange-rate assumptions on which it rests.

Insight 2: MRP approval falls between customs clearance and sale, which is an awkward position. The application file includes a copy of the customs clearance and the bill of entry, which means it can only be lodged once the goods have arrived and been cleared. The consequence is that after arrival the goods wait a further 30 to 40 days before they can be offered for sale, and the storage cost during that period belongs in the landed cost calculation, not in a contingency line. It also means the cash conversion cycle for a first shipment is longer than a registration-only plan would suggest.

Insight 3: price offences were already explicit in the old ordinance, and the 2023 law continues in a stricter direction. Under the 1982 ordinance, selling above the government-approved maximum price was punishable by up to 2 years imprisonment and a fine of up to 10,000 taka, as reported in the media. The 2023 law broadened the categories of prohibited conduct from 6 to 30, and stricter enforcement is the direction of travel. For a distributor, the practical risk is asymmetric: the margin gained by exceeding the MRP is small, and the exposure is personal as well as corporate.

Insight 4: the label and the price are one workstream. Because the MRP must appear on the pack, and the pack cannot be completed until the figure is approved, the pricing decision sets the labelling date. A late pricing decision delays release even when the goods, the label stock and the warehouse are all ready.

4. Practical recommendations

GRZAN schedules 30 to 40 days for MRP as a separate line in the pre-launch plan, rather than absorbing it into the clearance timeline. We ask clients to settle the target retail price range and the exchange-rate assumption during registration, because the MRP is denominated in taka and currency movement feeds directly into realised revenue. Our recommendation is to declare on the basis of the highest price the product may reach within the next 5 years, which preserves room for later adjustment, and then to sell below the ceiling at a level the market will bear. The headroom is what makes the approval durable; a figure set at today’s price has to be re-approved as soon as costs move.

• Schedule the approval as its own task. 30 to 40 days after clearance, not inside it.
• Decide the price band early. Target retail range and exchange-rate assumption fixed at registration.
• Declare for the 5-year horizon. A ceiling set at today’s price invites a re-approval.
• Reserve the label position. The MRP field is designed before the figure is known, in taka.
• Tell the channel in writing. Distributors should have the ceiling and the consequence of exceeding it on record.

5. Verification checklist

• □ MRP approval included in the pre-launch plan with 30 to 40 days reserved
• □ Application documents assembled: registration certificate copy, approved proforma invoice, customs clearance copy, commercial invoice, bill of entry
• □ MRP declared on the basis of the highest price reachable within 5 years
• □ Label carries a reserved MRP position, stated in taka
• □ Additional labelling under §7.2 Note 3 completed before release for sale
• □ Compliance risk of selling above the MRP communicated to channel partners in writing

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com